These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 30048718)

  • 41. [Docetaxel plus prednisone versus mitoxantrone plus prednisone as first-line chemotherapy for metastatic hormone-refractory prostate cancer: long-term effects and safety].
    Shen YJ; Bian XJ; Xie HY; Zhu Y; Zhang HL; Dai B; Zhang SL; Yao XD; Ye DW
    Zhonghua Wai Ke Za Zhi; 2012 Jun; 50(6):539-42. PubMed ID: 22943949
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
    Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
    Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.
    Chang K; Kong YY; Dai B; Ye DW; Qu YY; Wang Y; Jia ZW; Li GX
    Oncotarget; 2015 Dec; 6(39):41825-36. PubMed ID: 26497689
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study.
    Joly F; Delva R; Mourey L; Sevin E; Bompas E; Vedrine L; Ravaud A; Eymard JC; Tubiana-Mathieu N; Linassier C; Houede N; Guillot A; Ringensen F; Cojocarasu O; Valenza B; Leconte A; Lheureux S; Clarisse B; Oudard S
    BJU Int; 2015 Jan; 115(1):65-73. PubMed ID: 24180479
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Second-line therapy in patients with metastatic castration-resistant prostate cancer with progression after or under docetaxel: A systematic review of nine randomized controlled trials.
    Poorthuis MHF; Vernooij RWM; van Moorselaar RJA; de Reijke TM
    Semin Oncol; 2017 Oct; 44(5):358-371. PubMed ID: 29580437
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
    Saad F; Fizazi K; Jinga V; Efstathiou E; Fong PC; Hart LL; Jones R; McDermott R; Wirth M; Suzuki K; MacLean DB; Wang L; Akaza H; Nelson J; Scher HI; Dreicer R; Webb IJ; de Wit R;
    Lancet Oncol; 2015 Mar; 16(3):338-48. PubMed ID: 25701170
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial.
    Climent MA; Font A; Durán I; Puente J; José Méndez-Vidal M; Sáez MI; Santander Lobera C; Ángel Arranz Arija J; González-Del-Alba A; Sánchez-Hernandez A; Juan Fita MJ; Esteban E; Alonso-Gordoa T; Mellado Gonzalez B; Maroto P; Lázaro-Quintela M; Cassinello-Espinosa J; Pérez-Valderrama B; Garcias C; Castellano D
    Eur J Cancer; 2022 Nov; 175():110-119. PubMed ID: 36099670
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study.
    Thiery-Vuillemin A; Poulsen MH; Lagneau E; Ploussard G; Birtle A; Dourthe LM; Beal-Ardisson D; Pintus E; Trepiakas R; Lefresne F; Lukac M; Van Sanden S; Pissart G; Reid A;
    Eur Urol; 2020 Mar; 77(3):380-387. PubMed ID: 31594705
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer.
    Zhou T; Zeng SX; Ye DW; Wei Q; Zhang X; Huang YR; Ye ZQ; Yang Y; Zhang W; Tian Y; Zhou FJ; Jie J; Chen SP; Sun Y; Xie LP; Yao X; Na YQ; Sun YH
    PLoS One; 2015; 10(1):e0117002. PubMed ID: 25625938
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
    Zhang HL; Ye DW; Yao XD; Dai B; Zhang SL; Shen YJ; Zhu Y; Zhang W
    Urol Int; 2007; 79(4):307-11. PubMed ID: 18025847
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study.
    Conteduca V; Wetterskog D; Castro E; Scarpi E; Romero-Laorden N; Gurioli G; Jayaram A; Lolli C; Schepisi G; Wingate A; Casadei C; Lozano R; Brighi N; Aragón IM; Marin-Aguilera M; Gonzalez-Billalabeitia E; Mellado B; Olmos D; Attard G; De Giorgi U
    Eur J Cancer; 2021 Jul; 152():49-59. PubMed ID: 34077818
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study.
    Vaishampayan U; Shevrin D; Stein M; Heilbrun L; Land S; Stark K; Li J; Dickow B; Heath E; Smith D; Fontana J
    Urology; 2015 Dec; 86(6):1206-11. PubMed ID: 26375845
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
    de Bono JS; Chowdhury S; Feyerabend S; Elliott T; Grande E; Melhem-Bertrandt A; Baron B; Hirmand M; Werbrouck P; Fizazi K
    Eur Urol; 2018 Jul; 74(1):37-45. PubMed ID: 28844372
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Which drug combination for hormone-refractory prostate cancer?
    Doggrell SA
    Expert Opin Pharmacother; 2005 Apr; 6(4):667-70. PubMed ID: 15934892
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy.
    Satoh T; Uemura H; Tanabe K; Nishiyama T; Terai A; Yokomizo A; Nakatani T; Imanaka K; Ozono S; Akaza H
    Jpn J Clin Oncol; 2014 Dec; 44(12):1206-15. PubMed ID: 25425730
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.
    Sonpavde G; Pond GR; Armstrong AJ; Galsky MD; Leopold L; Wood BA; Wang SL; Paolini J; Chen I; Chow-Maneval E; Mooney DJ; Lechuga M; Smith MR; Michaelson MD
    BJU Int; 2014 Dec; 114(6b):E25-E31. PubMed ID: 24298897
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.
    Araujo JC; Trudel GC; Saad F; Armstrong AJ; Yu EY; Bellmunt J; Wilding G; McCaffrey J; Serrano SV; Matveev VB; Efstathiou E; Oudard S; Morris MJ; Sizer B; Goebell PJ; Heidenreich A; de Bono JS; Begbie S; Hong JH; Richardet E; Gallardo E; Paliwal P; Durham S; Cheng S; Logothetis CJ
    Lancet Oncol; 2013 Dec; 14(13):1307-16. PubMed ID: 24211163
    [TBL] [Abstract][Full Text] [Related]  

  • 58. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.
    Podrazil M; Horvath R; Becht E; Rozkova D; Bilkova P; Sochorova K; Hromadkova H; Kayserova J; Vavrova K; Lastovicka J; Vrabcova P; Kubackova K; Gasova Z; Jarolim L; Babjuk M; Spisek R; Bartunkova J; Fucikova J
    Oncotarget; 2015 Jul; 6(20):18192-205. PubMed ID: 26078335
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel.
    Ryan CJ; Dutta S; Kelly WK; Middleberg R; Russell C; Morris MJ; Taplin ME; Halabi S;
    Clin Genitourin Cancer; 2020 Jun; 18(3):222-229.e2. PubMed ID: 32273234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.